ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

GlaxoSmithKline, Bristol-Myers Squibb and AbbVie side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

GlaxoSmithKline×Bristol-Myers Squibb×AbbVie×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

GlaxoSmithKlineBristol-Myers SquibbAbbVie
studies on the registry4,1982,1842,251
open to participants now135155133
phase 3 studies under way768274
reach primary completion within a year666790
programswith a study of their own in two years85+17 named only57+9 named only70+8 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseGlaxoSmithKlineBristol-Myers SquibbAbbVie
Phase 1

GlaxoSmithKline: 18 of its 85 programs at phase 1

  1. Pn-MAPS30plusphase 1
  2. GSK4771261phase 1
  3. Antibody-drug Conjugate GSK5533524phase 1
  4. ganfeborolephase 1
  5. GSK4425689Aphase 1

and 13 more — sign in to see them all

21%

Bristol-Myers Squibb: 17 of its 57 programs at phase 1

  1. BMS-986454phase 1
  2. orevandrodegphase 1
  3. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1
  4. BMS-985521phase 1
  5. BMS-986485phase 1

and 12 more — sign in to see them all

30%

AbbVie: 28 of its 70 programs at phase 1

  1. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1
  2. surzetoclaxphase 1
  3. BTK Degrader ABBV-101phase 1
  4. ABBV-1162phase 1
  5. ABBV-1451phase 1

and 23 more — sign in to see them all

40%
Phase 2

GlaxoSmithKline: 34 of its 85 programs at phase 2

  1. dezecapavirphase 2
  2. nelistotugphase 2
  3. GSK3862995Bphase 2
  4. VH4524184phase 2
  5. nirogacestatphase 2

and 29 more — sign in to see them all

40%

Bristol-Myers Squibb: 17 of its 57 programs at phase 2

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. delocamtenphase 2
  4. imzokitugphase 2
  5. Cyclophosphamidephase 2

and 12 more — sign in to see them all

30%

AbbVie: 20 of its 70 programs at phase 2

  1. ABBV-295phase 2
  2. zumilokibartphase 2
  3. ABBV-932phase 2
  4. trosunilimabphase 2
  5. ABBV-701phase 2

and 15 more — sign in to see them all

29%
Phase 3

GlaxoSmithKline: 23 of its 85 programs at phase 3

  1. belantamab mafodotinphase 3
  2. felcorekibartphase 3
  3. risvutatug rezetecanphase 3
  4. velzatinibphase 3
  5. efimosfermin alfaphase 3

and 18 more — sign in to see them all

27%

Bristol-Myers Squibb: 16 of its 57 programs at phase 3

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. golcadomidephase 3
  5. zolacabtagene autoleucelphase 3

and 11 more — sign in to see them all

28%

AbbVie: 16 of its 70 programs at phase 3

  1. telisotuzumab adizutecanphase 3
  2. etentamigphase 3
  3. lutikizumabphase 3
  4. mirvetuximab soravtansinephase 3
  5. turmetabart adizutecanphase 3

and 11 more — sign in to see them all

23%
Approved, new studies

GlaxoSmithKline: 10 of its 85 programs at approved, new studies

  1. dostarlimabapproved, new study
  2. cabotegravirapproved, new study
  3. depemokimabapproved, new study
  4. belimumabapproved, new study
  5. niraparibapproved, new study

and 5 more — sign in to see them all

12%

Bristol-Myers Squibb: 7 of its 57 programs at approved, new studies

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. deucravacitinibapproved, new study
  4. Nivolumabapproved, new study
  5. trospium chlorideapproved, new study

and 2 more — sign in to see them all

12%

AbbVie: 6 of its 70 programs at approved, new studies

  1. upadacitinibapproved, new study
  2. risankizumabapproved, new study
  3. venetoclaxapproved, new study
  4. botulinum toxin type Aapproved, new study
  5. atogepantapproved, new study

and 1 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
GlaxoSmithKline38 readouts · 8 phase 3

GlaxoSmithKline, Nov ’26: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. dostarlimabapproved, new study · Nov 23 · NCT06567782
  2. Pentetic Acidphase 3 · Nov 23 · NCT07596199
  3. niraparibapproved, new study · Nov 26 · NCT03981796

GlaxoSmithKline, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccinephase 1 · Dec 3 · NCT07464314
  2. momelotinibphase 3 · Dec 11 · NCT03441113
  3. GSK3862995Bphase 2 · Dec 16 · NCT06154837
  4. HFA-152aphase 3 · Dec 28 · NCT07645248
  5. norfluranephase 3 · Dec 28 · NCT07645248

and 1 more — sign in to see them all

GlaxoSmithKline, Jan ’27: 4 programs whose next study reaches primary completion

  1. Adjuvanted RSVPreF3 vaccinephase 2 · Jan 12 · NCT07092865
  2. velzatinibphase 3 · Jan 12 · NCT07862114
  3. SOC INSTI-based ARTphase 1 · Jan 22 · NCT07053384
  4. VH3810109phase 2 · Jan 22 · NCT07053384

GlaxoSmithKline, Feb ’27: 2 programs whose next study reaches primary completion

  1. dezecapavirphase 2 · Feb 18 · NCT07934719
  2. Pn-MAPS30plusphase 1 · Feb 22 · NCT07406334

GlaxoSmithKline, Mar ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. depemokimabapproved, new study · Mar 1 · NCT07671001
  2. CAB ULAphase 3 · Mar 8 · NCT06786520
  3. cabotegravirapproved, new study · Mar 8 · NCT06786520
  4. camlipixantphase 3 · Mar 9 · NCT07519395
  5. ozureprubartphase 2 · Mar 16 · NCT07220811

and 1 more — sign in to see them all

GlaxoSmithKline, Apr ’27: 2 programs whose next study reaches primary completion

  1. felcorekibartphase 3 · Apr 13 · NCT07712393
  2. as01ephase 2 · Apr 23 · NCT07036159

GlaxoSmithKline, May ’27: 3 programs whose next study reaches primary completion

  1. VH4770359phase 1 · May 5 · NCT07525544
  2. gepotidacinphase 3 · May 17 · NCT07645235
  3. GSK4771261phase 1 · May 20 · NCT07600450

GlaxoSmithKline, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Bevacizumabphase 2 · Jun 21 · NCT06796907
  2. belimumabapproved, new study · Jun 29 · NCT06411249
  3. Low dose Strep A Alumphase 1 · Jun 29 · NCT07085702
  4. Low dose Strep A AS37phase 1 · Jun 29 · NCT07085702

GlaxoSmithKline, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mRNA Seasonal Flu vaccinephase 3 · Jul 9 · NCT07851246

GlaxoSmithKline, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. belantamabphase 2 · Aug 5 · NCT07742527
  2. shingrixapproved, new study · Aug 23 · NCT05371080

GlaxoSmithKline, Sep ’27: 1 program whose next study reaches primary completion

  1. mocertatug rezetecanphase 3 · Sep 22 · NCT06431594

GlaxoSmithKline, Oct ’27: 4 programs whose next study reaches primary completion

  1. GSK3772701phase 2 · Oct 8 · NCT07545681
  2. efimosfermin alfaphase 3 · Oct 13 · NCT07358546
  3. Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514phase 2 · Oct 26 · NCT06990880
  4. VH4524184phase 2 · Oct 28 · NCT07202546
Bristol-Myers Squibb22 readouts · 7 phase 3

Bristol-Myers Squibb, Nov ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. trospiumapproved, new study · Nov 24 · NCT06585787
  2. xanomelineapproved, new study · Nov 24 · NCT06585787

Bristol-Myers Squibb, Dec ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. actinium AC-225 dotatatephase 3 · Dec 0 · NCT05477576
  2. navlimetostatphase 3 · Dec 5 · NCT07777133
  3. delocamtenphase 2 · Dec 14 · NCT06122779
  4. golcadomidephase 3 · Dec 14 · NCT07763418
  5. moponetugphase 2 · Dec 17 · NCT06268886

and 2 more — sign in to see them all

Bristol-Myers Squibb, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mezigdomidephase 3 · Jan 10 · NCT05519085

Bristol-Myers Squibb, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1 · Feb 0 · NCT07165132
  2. Nivolumabapproved, new study · Feb 5 · NCT06946797
  3. repotrectinibphase 3 · Feb 16 · NCT06140836

Bristol-Myers Squibb, Mar ’27: 1 program whose next study reaches primary completion

  1. trospium chlorideapproved, new study · Mar 29 · NCT07063342
·

Bristol-Myers Squibb, May ’27: 1 program whose next study reaches primary completion

  1. elranatamabphase 2 · May 31 · NCT06988488

Bristol-Myers Squibb, Jun ’27: 3 programs whose next study reaches primary completion

  1. BMS-986533phase 1 · Jun 1 · NCT07629999
  2. BMS-986485phase 1 · Jun 8 · NCT07887763
  3. BMS-986454phase 1 · Jun 28 · NCT07171983

Bristol-Myers Squibb, Jul ’27: 1 program whose next study reaches primary completion

  1. zolacabtagene autoleucelphase 3 · Jul 15 · NCT06220201

Bristol-Myers Squibb, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. atigotatugphase 3 · Aug 17 · NCT06646276

Bristol-Myers Squibb, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. dezandrodegphase 3 · Sep 12 · NCT06764485

Bristol-Myers Squibb, Oct ’27: 1 program whose next study reaches primary completion

  1. BMS-986488phase 1 · Oct 15 · NCT06764771
AbbVie34 readouts · 5 phase 3

AbbVie, Nov ’26: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-701phase 2 · Nov 0 · NCT06895343
  2. ABBV-932phase 2 · Nov 0 · NCT06846320
  3. mirvetuximab soravtansinephase 3 · Nov 0 · NCT05456685
  4. upadacitinibapproved, new study · Nov 0 · NCT06389136
  5. venetoclaxapproved, new study · Nov 0 · NCT04895436

and 1 more — sign in to see them all

AbbVie, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-295phase 2 · Dec 0 · NCT07514260
  2. emraclidinephase 2 · Dec 0 · NCT07219030
  3. lutikizumabphase 3 · Dec 0 · NCT06468228
  4. telisotuzumab adizutecanphase 3 · Dec 0 · NCT06107413

AbbVie, Jan ’27: 1 program whose next study reaches primary completion

  1. risankizumabapproved, new study · Jan 0 · NCT07466550

AbbVie, Feb ’27: 9 programs whose next study reaches primary completion

  1. [11C]ABBV-112iearly phase 1 · Feb 0 · NCT07933497
  2. ABBV-859phase 1 · Feb 0 · NCT07736638
  3. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1 · Feb 0 · NCT05512390
  4. etentamigphase 3 · Feb 0 · NCT06223516
  5. MEDI0618phase 2 · Feb 0 · NCT06602479

and 4 more — sign in to see them all

·

AbbVie, Apr ’27: 1 program whose next study reaches primary completion

  1. ABBV-1451phase 1 · Apr 0 · NCT07570147

AbbVie, May ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-1162phase 1 · May 0 · NCT07832708
  2. ABBV-243phase 1 · May 0 · NCT07306754
  3. ABBV-7828phase 1 · May 0 · NCT07856706
  4. Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969phase 1 · May 0 · NCT06318273
  5. trosunilimabphase 2 · May 0 · NCT07925983

and 1 more — sign in to see them all

AbbVie, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. botulinum toxin type Aapproved, new study · Jun 0 · NCT07794891

AbbVie, Jul ’27: 4 programs whose next study reaches primary completion

  1. ABBV-1606phase 1 · Jul 0 · NCT07935564
  2. azirkitugphase 1 · Jul 0 · NCT05005403
  3. surzetoclaxphase 2 · Jul 0 · NCT06291220
  4. surzetoclaxphase 1 · Jul 0 · NCT06291220

AbbVie, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. vedolizumabphase 3 · Aug 0 · NCT06880744

AbbVie, Sep ’27: 1 program whose next study reaches primary completion

  1. icalcaprantphase 2 · Sep 0 · NCT07276997
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 24, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

GlaxoSmithKline

New programs 4

Reached a new phase 0

None

Study stopped 2

  • camlipixantphase 3 · terminated Nov 20“The study has been terminated due to the decision to cease further development of camlipixant in refractory…” · NCT05600777
  • camlipixantphase 3 · terminated Nov 20“The study has been withdrawn terminated due to the decision to cease further development of camlipixant in …” · NCT07650084

Primary completion later 10

Bristol-Myers Squibb

New programs 5

  • BMS-986548phase 2 · first study · Nov 10
  • BMS-986485phase 1 · first study · Oct 14
  • BMS-986553phase 1 · first study · Oct 8 · Lupus Nephritis
  • RYZ711phase 2 · first study · Oct 1 · Prostatic Neoplasms
  • BMS-986527phase 1 · first study · Sep 22 · Carcinoma, Renal Cell

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

AbbVie

New programs 5

Reached a new phase 1

  • ABBV-722phase 3 · Oct 23 · Scleroderma, Systemic

Study stopped 0

None

Primary completion later 10

Where they overlap

Conditions where at least two of them have programs: 44 in all. A program counts in each condition its studies name most.

ConditionGlaxoSmithKlineBristol-Myers SquibbAbbVie
Carcinoma, Non-Small-Cell Lungall three · compare here

GlaxoSmithKline in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. risvutatug rezetecanphase 3
  2. momelotinibphase 3
  3. neladalkibphase 3
  4. feladilimabphase 3
  5. nelistotugphase 2

and 3 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Carcinoma, Non-Small-Cell Lung in search

Bristol-Myers Squibb in Carcinoma, Non-Small-Cell Lung: 11 programs

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. izalontamab brengitecanphase 3
  5. repotrectinibphase 3

and 6 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Non-Small-Cell Lung in search

AbbVie in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. telisotuzumab adizutecanphase 3
  2. ABBV-1480phase 3
  3. azirkitugphase 1
  4. RC148no phase

Their studies: AbbVie’s studies of Carcinoma, Non-Small-Cell Lung in search

Multiple Myelomaall three · compare here

GlaxoSmithKline in Multiple Myeloma: 5 programs

  1. belantamab mafodotinphase 3
  2. feladilimabphase 3
  3. nirogacestatphase 2
  4. belantamabphase 2
  5. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Multiple Myeloma in search

Bristol-Myers Squibb in Multiple Myeloma: 6 programs

  1. mezigdomidephase 3
  2. arlocabtagene autoleucelphase 3
  3. Cyclophosphamidephase 2
  4. elranatamabphase 2
  5. fludarabinephase 1

and 1 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Multiple Myeloma in search

Neoplasmsall three · compare here

Bristol-Myers Squibb in Neoplasms: 5 programs

  1. repotrectinibphase 3
  2. BMS-986488phase 1
  3. BMS-986500phase 1
  4. Digoxinphase 1
  5. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Neoplasms in search

Alzheimer Diseaseall three · compare here

GlaxoSmithKline in Alzheimer Disease: 1 program

  1. nivisnebartphase 2

Their studies: GlaxoSmithKline’s studies of Alzheimer Disease in search

Bristol-Myers Squibb in Alzheimer Disease: 5 programs

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. xanomelineapproved, new study
  4. trospiumapproved, new study
  5. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Alzheimer Disease in search

AbbVie in Alzheimer Disease: 3 programs

  1. emraclidinephase 2
  2. ABBV-1758phase 2
  3. ALIA-1758phase 1

Their studies: AbbVie’s studies of Alzheimer Disease in search

Arthritis, Rheumatoidall three · compare here

GlaxoSmithKline in Arthritis, Rheumatoid: 1 program

  1. belimumabapproved, new study

Their studies: GlaxoSmithKline’s studies of Arthritis, Rheumatoid in search

Bristol-Myers Squibb in Arthritis, Rheumatoid: 3 programs

  1. tocilizumabphase 3
  2. BMS-986528phase 2
  3. BMS-986454phase 1

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Rheumatoid in search

AbbVie in Arthritis, Rheumatoid: 5 programs

  1. lutikizumabphase 3
  2. ABBV-722phase 3
  3. ravagalimabphase 2
  4. CPTX2309phase 1
  5. upadacitinibapproved, new study

Their studies: AbbVie’s studies of Arthritis, Rheumatoid in search

Breast Neoplasmsall three · compare here

GlaxoSmithKline in Breast Neoplasms: 3 programs

  1. nirogacestatphase 2
  2. Bevacizumabphase 2
  3. niraparibapproved, new study

Their studies: GlaxoSmithKline’s studies of Breast Neoplasms in search

Bristol-Myers Squibb in Breast Neoplasms: 4 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. actinium AC-225 dotatatephase 3
  4. Cyclophosphamidephase 2

Their studies: Bristol-Myers Squibb’s studies of Breast Neoplasms in search

AbbVie in Breast Neoplasms: 2 programs

  1. trifluridine tipiracil drug combinationphase 3
  2. RC148no phase

Their studies: AbbVie’s studies of Breast Neoplasms in search

Colorectal Neoplasmsall three · compare here

Bristol-Myers Squibb in Colorectal Neoplasms: 3 programs

  1. pumitamigphase 3
  2. adagrasibphase 3
  3. Nivolumabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Colorectal Neoplasms in search

AbbVie in Colorectal Neoplasms: 3 programs

  1. telisotuzumab adizutecanphase 3
  2. trifluridine tipiracil drug combinationphase 3
  3. RC148no phase

Their studies: AbbVie’s studies of Colorectal Neoplasms in search

Small Cell Lung Carcinomaall three · compare here

GlaxoSmithKline in Small Cell Lung Carcinoma: 2 programs

  1. risvutatug rezetecanphase 3
  2. ivonescimabphase 2

Their studies: GlaxoSmithKline’s studies of Small Cell Lung Carcinoma in search

Bristol-Myers Squibb in Small Cell Lung Carcinoma: 5 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. atigotatugphase 3
  4. BMS-986525phase 2
  5. atigotatugphase 2

Their studies: Bristol-Myers Squibb’s studies of Small Cell Lung Carcinoma in search

Lupus Erythematosus, Systemicall three · compare here

GlaxoSmithKline in Lupus Erythematosus, Systemic: 4 programs

  1. GSK5926371phase 2
  2. GSK4527363phase 1
  3. GSK4347859phase 1
  4. belimumabapproved, new study

Their studies: GlaxoSmithKline’s studies of Lupus Erythematosus, Systemic in search

Bristol-Myers Squibb in Lupus Erythematosus, Systemic: 3 programs

  1. zolacabtagene autoleucelphase 3
  2. obexelimabphase 3
  3. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Lupus Erythematosus, Systemic in search

AbbVie in Lupus Erythematosus, Systemic: 1 program

  1. ABBV-519phase 1

Their studies: AbbVie’s studies of Lupus Erythematosus, Systemic in search

Prostatic Neoplasmsall three · compare here

Bristol-Myers Squibb in Prostatic Neoplasms: 3 programs

  1. dezandrodegphase 3
  2. RYZ711phase 2
  3. orevandrodegphase 1

Their studies: Bristol-Myers Squibb’s studies of Prostatic Neoplasms in search

Colitis, Ulcerativeall three · compare here

GlaxoSmithKline in Colitis, Ulcerative: 2 programs

  1. aletekitugphase 2
  2. GSK4528287phase 1

Their studies: GlaxoSmithKline’s studies of Colitis, Ulcerative in search

Bristol-Myers Squibb in Colitis, Ulcerative: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Colitis, Ulcerative in search

AbbVie in Colitis, Ulcerative: 4 programs

  1. vedolizumabphase 3
  2. ravagalimabphase 2
  3. upadacitinibapproved, new study
  4. risankizumabapproved, new study

Their studies: AbbVie’s studies of Colitis, Ulcerative in search

Carcinoma, Hepatocellularall three · compare here

GlaxoSmithKline in Carcinoma, Hepatocellular: 1 program

  1. Bevacizumabphase 2

Their studies: GlaxoSmithKline’s studies of Carcinoma, Hepatocellular in search

Bristol-Myers Squibb in Carcinoma, Hepatocellular: 4 programs

  1. pumitamigphase 3
  2. Actinium Ac 225 GPC3-targeted Peptide RYZ801phase 2
  3. Nivolumabapproved, new study
  4. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Hepatocellular in search

AbbVie in Carcinoma, Hepatocellular: 1 program

  1. telisotuzumab adizutecanphase 3

Their studies: AbbVie’s studies of Carcinoma, Hepatocellular in search

Lymphoma, Non-Hodgkinall three · compare here

GlaxoSmithKline in Lymphoma, Non-Hodgkin: 1 program

  1. GSK5926371phase 2

Their studies: GlaxoSmithKline’s studies of Lymphoma, Non-Hodgkin in search

Bristol-Myers Squibb in Lymphoma, Non-Hodgkin: 3 programs

  1. golcadomidephase 3
  2. lisocabtagene maraleucelphase 3
  3. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, Non-Hodgkin in search

AbbVie in Lymphoma, Non-Hodgkin: 1 program

  1. venetoclaxapproved, new study

Their studies: AbbVie’s studies of Lymphoma, Non-Hodgkin in search

Anemia, Hemolytic, Autoimmuneall three · compare here

GlaxoSmithKline in Anemia, Hemolytic, Autoimmune: 1 program

  1. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Anemia, Hemolytic, Autoimmune in search

Bristol-Myers Squibb in Anemia, Hemolytic, Autoimmune: 2 programs

  1. zolacabtagene autoleucelphase 3
  2. obexelimabphase 3

Their studies: Bristol-Myers Squibb’s studies of Anemia, Hemolytic, Autoimmune in search

AbbVie in Anemia, Hemolytic, Autoimmune: 1 program

  1. pegcetacoplanphase 2

Their studies: AbbVie’s studies of Anemia, Hemolytic, Autoimmune in search

Scleroderma, Systemicall three · compare here

GlaxoSmithKline in Scleroderma, Systemic: 1 program

  1. belimumabapproved, new study

Their studies: GlaxoSmithKline’s studies of Scleroderma, Systemic in search

Bristol-Myers Squibb in Scleroderma, Systemic: 2 programs

  1. zolacabtagene autoleucelphase 3
  2. tocilizumabphase 3

Their studies: Bristol-Myers Squibb’s studies of Scleroderma, Systemic in search

AbbVie in Scleroderma, Systemic: 1 program

  1. ABBV-722phase 3

Their studies: AbbVie’s studies of Scleroderma, Systemic in search

Obesityall three · compare here

GlaxoSmithKline in Obesity: 1 program

  1. efimosfermin alfaphase 3

Their studies: GlaxoSmithKline’s studies of Obesity in search

Bristol-Myers Squibb in Obesity: 1 program

  1. Digoxinphase 1

Their studies: Bristol-Myers Squibb’s studies of Obesity in search

AbbVie in Obesity: 1 program

  1. ABBV-295phase 2

Their studies: AbbVie’s studies of Obesity in search

Crohn Disease2 of 3 · compare here–

Bristol-Myers Squibb in Crohn Disease: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Crohn Disease in search

AbbVie in Crohn Disease: 7 programs

  1. lutikizumabphase 3
  2. vedolizumabphase 3
  3. trosunilimabphase 2
  4. ABBV-701phase 2
  5. ABBV-8736phase 2

and 2 more — sign in to see them all

Their studies: AbbVie’s studies of Crohn Disease in search

Ovarian Neoplasms2 of 3 · compare here

GlaxoSmithKline in Ovarian Neoplasms: 6 programs

  1. mocertatug rezetecanphase 3
  2. nirogacestatphase 2
  3. Bevacizumabphase 2
  4. ivonescimabphase 2
  5. dostarlimabapproved, new study

and 1 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Ovarian Neoplasms in search

–
Asthma2 of 3 · compare here

GlaxoSmithKline in Asthma: 5 programs

  1. felcorekibartphase 3
  2. norfluranephase 3
  3. HFA-152aphase 3
  4. ozureprubartphase 2
  5. depemokimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Asthma in search

–

AbbVie in Asthma: 1 program

  1. zumilokibartphase 2

Their studies: AbbVie’s studies of Asthma in search

Leukemia, Lymphocytic, Chronic, B-Cell2 of 3 · compare here–

Bristol-Myers Squibb in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. lisocabtagene maraleucelphase 3
  2. Cyclophosphamidephase 2
  3. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

AbbVie in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. surzetoclaxphase 2
  2. surzetoclaxphase 1
  3. venetoclaxapproved, new study

Their studies: AbbVie’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Arthritis, Psoriatic2 of 3 · compare here–

Bristol-Myers Squibb in Arthritis, Psoriatic: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Psoriatic in search

AbbVie in Arthritis, Psoriatic: 4 programs

  1. lutikizumabphase 3
  2. ABBV-701phase 2
  3. ABBV-547phase 2
  4. risankizumabapproved, new study

Their studies: AbbVie’s studies of Arthritis, Psoriatic in search

Dermatitis, Atopic2 of 3 · compare here

GlaxoSmithKline in Dermatitis, Atopic: 2 programs

  1. camlipixantphase 3
  2. aletekitugphase 2

Their studies: GlaxoSmithKline’s studies of Dermatitis, Atopic in search

–

AbbVie in Dermatitis, Atopic: 3 programs

  1. zumilokibartphase 2
  2. APG990phase 1
  3. upadacitinibapproved, new study

Their studies: AbbVie’s studies of Dermatitis, Atopic in search

Acquired Immunodeficiency Syndrome2 of 3 · compare here

GlaxoSmithKline in Acquired Immunodeficiency Syndrome: 3 programs

  1. cabotegravirapproved, new study
  2. Dolutegravirapproved, new study
  3. Lamivudineapproved, new study

Their studies: GlaxoSmithKline’s studies of Acquired Immunodeficiency Syndrome in search

–

AbbVie in Acquired Immunodeficiency Syndrome: 1 program

  1. trosunilimabphase 2

Their studies: AbbVie’s studies of Acquired Immunodeficiency Syndrome in search

Lymphoma2 of 3 · compare here

GlaxoSmithKline in Lymphoma: 1 program

  1. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Lymphoma in search

Bristol-Myers Squibb in Lymphoma: 3 programs

  1. lisocabtagene maraleucelphase 3
  2. repotrectinibphase 3
  3. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Lymphoma in search

–
Psoriasis2 of 3 · compare here–

Bristol-Myers Squibb in Psoriasis: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Psoriasis in search

AbbVie in Psoriasis: 3 programs

  1. ABBV-295phase 2
  2. ABBV-547phase 2
  3. risankizumabapproved, new study

Their studies: AbbVie’s studies of Psoriasis in search

Pulmonary Disease, Chronic Obstructive2 of 3 · compare here

GlaxoSmithKline in Pulmonary Disease, Chronic Obstructive: 3 programs

  1. felcorekibartphase 3
  2. GSK3862995Bphase 2
  3. depemokimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Pulmonary Disease, Chronic Obstructive in search

Bristol-Myers Squibb in Pulmonary Disease, Chronic Obstructive: 1 program

  1. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Pulmonary Disease, Chronic Obstructive in search

–
Schizophrenia2 of 3 · compare here–

Bristol-Myers Squibb in Schizophrenia: 3 programs

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Schizophrenia in search

AbbVie in Schizophrenia: 1 program

  1. emraclidinephase 2

Their studies: AbbVie’s studies of Schizophrenia in search

Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here

GlaxoSmithKline in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. feladilimabphase 3
  2. nelistotugphase 2

Their studies: GlaxoSmithKline’s studies of Squamous Cell Carcinoma of Head and Neck in search

–

AbbVie in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. telisotuzumab adizutecanphase 3
  2. ABBV-711phase 1

Their studies: AbbVie’s studies of Squamous Cell Carcinoma of Head and Neck in search

Bipolar Disorder2 of 3 · compare here–

Bristol-Myers Squibb in Bipolar Disorder: 1 program

  1. Lithiumphase 1

Their studies: Bristol-Myers Squibb’s studies of Bipolar Disorder in search

AbbVie in Bipolar Disorder: 2 programs

  1. ABBV-932phase 2
  2. icalcaprantphase 2

Their studies: AbbVie’s studies of Bipolar Disorder in search

Depressive Disorder, Major2 of 3 · compare here–

Bristol-Myers Squibb in Depressive Disorder, Major: 1 program

  1. BMS-986511phase 2

Their studies: Bristol-Myers Squibb’s studies of Depressive Disorder, Major in search

AbbVie in Depressive Disorder, Major: 2 programs

  1. icalcaprantphase 2
  2. bretisilocinphase 2

Their studies: AbbVie’s studies of Depressive Disorder, Major in search

Endometrial Neoplasms2 of 3 · compare here

GlaxoSmithKline in Endometrial Neoplasms: 2 programs

  1. mocertatug rezetecanphase 3
  2. dostarlimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Endometrial Neoplasms in search

–

AbbVie in Endometrial Neoplasms: 1 program

  1. opugotamig olatansinephase 2

Their studies: AbbVie’s studies of Endometrial Neoplasms in search

Lymphoma, Large B-Cell, Diffuse2 of 3 · compare here–

Bristol-Myers Squibb in Lymphoma, Large B-Cell, Diffuse: 2 programs

  1. lisocabtagene maraleucelphase 3
  2. Cyclophosphamidephase 2

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, Large B-Cell, Diffuse in search

Melanoma2 of 3 · compare here–

Bristol-Myers Squibb in Melanoma: 2 programs

  1. Nivolumabapproved, new study
  2. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Melanoma in search

AbbVie in Melanoma: 1 program

  1. vedolizumabphase 3

Their studies: AbbVie’s studies of Melanoma in search

Neoplasm Metastasis2 of 3 · compare here

GlaxoSmithKline in Neoplasm Metastasis: 1 program

  1. neladalkibphase 3

Their studies: GlaxoSmithKline’s studies of Neoplasm Metastasis in search

Bristol-Myers Squibb in Neoplasm Metastasis: 2 programs

  1. adagrasibphase 3
  2. repotrectinibphase 3

Their studies: Bristol-Myers Squibb’s studies of Neoplasm Metastasis in search

–
Amyloidosis2 of 3 · compare here

GlaxoSmithKline in Amyloidosis: 1 program

  1. belantamab mafodotinphase 3

Their studies: GlaxoSmithKline’s studies of Amyloidosis in search

–

AbbVie in Amyloidosis: 1 program

  1. etentamigphase 3

Their studies: AbbVie’s studies of Amyloidosis in search

Arthritis, Juvenile2 of 3 · compare here–

Bristol-Myers Squibb in Arthritis, Juvenile: 1 program

  1. tocilizumabphase 3

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Juvenile in search

AbbVie in Arthritis, Juvenile: 1 program

  1. risankizumabapproved, new study

Their studies: AbbVie’s studies of Arthritis, Juvenile in search

Idiopathic Pulmonary Fibrosis2 of 3 · compare here–

Bristol-Myers Squibb in Idiopathic Pulmonary Fibrosis: 1 program

  1. admilparantphase 3

Their studies: Bristol-Myers Squibb’s studies of Idiopathic Pulmonary Fibrosis in search

AbbVie in Idiopathic Pulmonary Fibrosis: 1 program

  1. ABBV-142phase 2

Their studies: AbbVie’s studies of Idiopathic Pulmonary Fibrosis in search

Kidney Diseases2 of 3 · compare here

GlaxoSmithKline in Kidney Diseases: 1 program

  1. GSK4771261phase 1

Their studies: GlaxoSmithKline’s studies of Kidney Diseases in search

–

AbbVie in Kidney Diseases: 1 program

  1. trifluridine tipiracil drug combinationphase 3

Their studies: AbbVie’s studies of Kidney Diseases in search

Muscle Spasticity2 of 3 · compare here–

Bristol-Myers Squibb in Muscle Spasticity: 1 program

  1. irafamdastatphase 2

Their studies: Bristol-Myers Squibb’s studies of Muscle Spasticity in search

AbbVie in Muscle Spasticity: 1 program

  1. botulinum toxin type Aapproved, new study

Their studies: AbbVie’s studies of Muscle Spasticity in search

Precursor Cell Lymphoblastic Leukemia-Lymphoma2 of 3 · compare here

GlaxoSmithKline in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

Bristol-Myers Squibb in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

–
Stomach Neoplasms2 of 3 · compare here–

Bristol-Myers Squibb in Stomach Neoplasms: 1 program

  1. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Stomach Neoplasms in search

AbbVie in Stomach Neoplasms: 1 program

  1. trifluridine tipiracil drug combinationphase 3

Their studies: AbbVie’s studies of Stomach Neoplasms in search

Stroke2 of 3 · compare here–

Bristol-Myers Squibb in Stroke: 1 program

  1. milvexianphase 2

Their studies: Bristol-Myers Squibb’s studies of Stroke in search

AbbVie in Stroke: 1 program

  1. botulinum toxin type Aapproved, new study

Their studies: AbbVie’s studies of Stroke in search

Triple Negative Breast Neoplasms2 of 3 · compare here

GlaxoSmithKline in Triple Negative Breast Neoplasms: 1 program

  1. ivonescimabphase 2

Their studies: GlaxoSmithKline’s studies of Triple Negative Breast Neoplasms in search

Bristol-Myers Squibb in Triple Negative Breast Neoplasms: 1 program

  1. izalontamab brengitecanphase 3

Their studies: Bristol-Myers Squibb’s studies of Triple Negative Breast Neoplasms in search

–
Urinary Bladder, Overactive2 of 3 · compare here–

Bristol-Myers Squibb in Urinary Bladder, Overactive: 1 program

  1. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Urinary Bladder, Overactive in search

AbbVie in Urinary Bladder, Overactive: 1 program

  1. botulinum toxin type Aapproved, new study

Their studies: AbbVie’s studies of Urinary Bladder, Overactive in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: GlaxoSmithKline 63 of 85 · Bristol-Myers Squibb 32 of 57 · AbbVie 54 of 70 programs (44 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (GlaxoSmithKline: 17, Bristol-Myers Squibb: 9, AbbVie: 8).